Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Fulcrum Therapeutics Inc Market Cap
From what 0 stock analysts predict, the share price for Fulcrum Therapeutics Inc (FULC) might increase by 406.6% in the next year. This is based on a 12-month average estimation for FULC. Price targets go from $5 to $26. The majority of stock analysts believe FULC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned FULC 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Fulcrum Therapeutics Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on FULC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of FULC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Andrew Fein HC Wainwright & Co. | Buy | $17 | Reiterates | Aug 1, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $23 | Reiterates | Jul 10, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $23 | Initiates | May 20, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $17 | Reiterates | May 14, 2024 |
| Corinne Jenkins Goldman Sachs | Buy | $15 | Upgrade | May 14, 2024 |
| Matthew Biegler Oppenheimer | Outperform | $14 | Maintains | May 14, 2024 |
| Corinne Jenkins Goldman Sachs | Buy | $15 | Upgrade | May 13, 2024 |
| Gregory Renza RBC Capital | Outperform | $14 | Initiates | Mar 13, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $15 | Maintains | Feb 28, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $17 | Maintains | Feb 28, 2024 |
| Madhu Kumar Goldman Sachs | Neutral | $6 | Maintains | Jan 26, 2024 |
| Madhu Kumar Goldman Sachs | Neutral | $6 | Maintains | Jan 25, 2024 |
| Madhu Kumar Goldman Sachs | Neutral | $5 | Initiates | Sep 25, 2023 |
| Andrew Fein HC Wainwright & Co. | Buy | $14 | Upgrade | Aug 23, 2023 |
| Dae Gon Ha Stifel | Buy | $11 | Upgrade | Aug 22, 2023 |
| Matthew Biegler Oppenheimer | Outperform | $16 | Reiterates | Aug 22, 2023 |
HC Wainwright & Co. | Neutral | Reiterates | Aug 4, 2023 | |
| Matthew Biegler Oppenheimer | Outperform | $16 | Maintains | May 16, 2023 |
| Andrew Fein HC Wainwright & Co. | Neutral | $5 | Maintains | May 16, 2023 |
| Madhu Kumar Goldman Sachs | Neutral | $3 | Maintains | May 5, 2023 |
When did it IPO
2019
Staff Count
76
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Alexander C. Sapir
Market Cap
$552.6M
In 2023, FULC generated $2.8M in revenue, which was a decrease of -55.77% from the previous year. This can be seen as a signal that FULC's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
